Inclusion Criteria for the Study:

        Unless otherwise noted, subjects must meet all of the following criteria to participate in
        all stages of this study:

          -  Written informed consent and HIPAA authorization for release of personal health
             information.

          -  Adults ≥18 years of age.

          -  Histologically confirmed B-cell NHL, including the following types defined by WHO
             2016:

        Aggressive Lymphomas:

          -  DLBCL not otherwise specified (NOS)

          -  T cell/histiocyte rich large B cell lymphoma; primary cutaneous DLBCL, leg type;
             EBV-positive DLBCL NOS; DLBCL associated with chronic inflammation; Lymphomatoid
             granulomatosis; Large B-cell lymphoma with IRF4 rearrangement; Intravascular large
             B-cell lymphoma; ALK-positive large B-cell lymphoma

          -  Primary mediastinal (thymic) large B-cell lymphoma

          -  High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement; high grade
             B-cell lymphoma, NOS

          -  B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and
             classical Hodgkin lymphoma

          -  Transformation of indolent lymphoma or CLL to DLBCL will also be included

          -  Burkitt lymphoma

        Indolent Lymphomas:

          -  Follicular lymphoma

          -  Splenic marginal zone lymphoma

          -  Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

          -  Nodal marginal zone lymphoma

          -  Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)

          -  Mantle cell lymphoma

          -  Subjects with CNS disease will not be excluded as long it has been stable for 3 months

             --For aggressive lymphomas, must have relapsed or refractory disease after having
             received at least 2 prior lines of systemic therapy, including, at a minimum:

          -  An anti-CD20 monoclonal antibody

          -  An anthracycline containing chemotherapy regimen (if eligible)

          -  An autologous stem cell transplant (if eligible)

               -  For indolent lymphomas, subjects must have received at least 2 prior lines of
                  therapy for their lymphoma

               -  Subjects relapsed after allogeneic stem cell transplant will be eligible if they
                  meet other inclusion criteria and have no active graft vs host disease (GVHD)

               -  Measurable or assessable disease by Lugano criteria

               -  Karnofsky score of > 60%

               -  Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth
                  control or be surgically sterile, or abstain from heterosexual activity for the
                  course of the study, and for 6 months after the study is concluded. WOCBP are
                  those who have not been surgically sterilized or have not been free from menses
                  for > 1 year. The two birth control methods can be composed of: two barrier
                  methods or a barrier method plus a hormonal method to prevent pregnancy. WOCBP
                  subjects will also be instructed to tell their male partners to use a condom.

        Exclusion Criteria for the Study:

        Subjects meeting any of the following exclusion criteria will not be able to participate in
        this study (procurement, lymphodepletion and cell infusion):

          -  Subject is pregnant or lactating.

          -  Tumor in a location where enlargement could cause airway obstruction.

          -  Current use of systemic corticosteroids at doses ≥10mg prednisone daily or its
             equivalent; those receiving <10mg daily may be enrolled at discretion of investigator.

          -  Active infection with HIV, HTLV, HBV, HCV (can be pending at the time of cell
             procurement; only those samples confirming lack of active infection will be used to
             generate transduced cells) defined as not being well controlled on therapy. Subjects
             are required to have negative HIV antibody, negative HTLV1 and HTLV2 antibodies,
             negative Hepatitis B surface antigen, and negative HCV antibody or viral load. In
             addition, subjects with positive Hepatitis B core antibody, will have Hepatitis B
             viral load tested and subjects with positive Hepatitis B viral load will also be
             excluded.

          -  Subject must either have core antibody negative HBV (results can be pending at the
             time of cell procurement) OR if a subject is hepatitis B core antibody positive they
             must have their hepatitis B viral load checked. These subjects will be excluded if
             their viral load is positive at baseline. Subjects who are core antibody positive and
             viral load negative at baseline will be considered eligible.

          -  Known additional malignancy that is active and/or progressive requiring treatment;
             exceptions include basal cell or squamous cell skin cancer, in situ cervical or
             bladder cancer, or other cancer for which the subject has been disease-free for at
             least five years.

          -  A history of intolerance to fludarabine. Note: subjects with history of intolerance to
             bendamustine may be considered for enrollment at the discretion of the clinical
             investigator if they are candidates for lymphodepletion with cyclophosphamide and
             fludarabine.

        Eligibility criteria to be met prior to procurement:

          -  Subjects must sign a consent to undergo cell procurement.

          -  Life expectancy ≥ 12 weeks.

          -  Evidence of adequate organ function as defined by:

        The following is required within 7 days prior to procurement:

          -  Bilirubin ≤1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome
             may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated
             bilirubin is <1.5× ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine Clearance (CrCl) >30mL/min per Cockcroft and Gault (See Section 12.3)

          -  Pulse oximetry of >90% on room air

               -  Left ventricular ejection fraction (LVEF) ≥35% as measured by ECHO, with no
                  additional evidence of decompensated heart failure.

               -  Imaging results from within 90 days prior to procurement to assess presence of
                  active disease.

               -  Negative serum pregnancy test within 72 hours prior to procurement or
                  documentation that the subject is post-menopausal. Post-menopausal status must be
                  confirmed with documentation of absence of menses for >1 year, or documentation
                  of surgical menopause involving bilateral oophorectomy.

        Eligibility criteria to be met prior to lymphodepletion:

          -  Written informed consent to enroll in the CAR T-cell therapy trial must be obtained
             prior to lymphodepletion.

          -  Imaging results from within 7 days prior to lymphodepletion. Imaging must occur at
             least 3 weeks after most recent therapy (used as baseline measure for documentation of
             progression before the lymphodepletion) to document measurable or assessable disease.
             Imaging does not need to be repeated if it is within 7 days prior to lymphodepletion.

          -  Evidence of adequate organ function as defined by:

        The following are required within 72 hours prior to lymphodepletion:

          -  Adequate bone marrow function (ANC ≥1.0 x 109/L and platelets ≥75 x 109/L). Subjects
             cannot have received platelet transfusion within 7 days of lymphodepletion.

          -  Bilirubin ≤1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome
             may be enrolled despite a total bilirubin level >1.5 mg/dL if their conjugated
             bilirubin is <1.5× ULN)

          -  AST ≤ 3 times ULN

          -  Creatinine Clearance (CrCl) >30mL/min per Cockcroft and Gault

          -  Pulse oximetry of > 90% on room air

               -  Negative serum pregnancy test within 72 hours prior to lymphodepletion or
                  documentation that the subject is post-menopausal. Post-menopausal status must be
                  confirmed with documentation of absence of menses for > 1 year, or documentation
                  of surgical menopause involving bilateral oophorectomy.

               -  Subjects that have received therapy with murine antibodies must have
                  documentation of absence of human anti-mouse antibodies (HAMA) prior to
                  lymphodepletion.

               -  Available autologous transduced activated T cells product meets the certificate
                  of analysis.

               -  Has not received any investigational agents or received any tumor vaccines within
                  the previous six weeks prior to lymphodepletion.

               -  Subject is not taking a prohibited or contraindicated medication prior to
                  lymphodepletion. Contraindicated medications should be discontinued at least two
                  weeks prior to the scheduled lymphodepletion or by at least 5 half-lives of the
                  contraindicated medication, whichever is shorter.

               -  Subject is not taking strong inhibitors of CYP1A2 (e.g., fluvoxamine,
                  ciprofloxacin) as these may increase plasma concentrations of bendamustine, and
                  decrease plasma concentrations of its metabolites. See
                  http://medicine.iupui.edu/clinpharm/ddis/ for an updated list of strong
                  inhibitors of CYP1A2. (This applies to subjects who receive bendamustine for
                  lymphodepletion (required) up through 72 hours after the last dose of
                  bendamustine).

               -  Subject has not received chemotherapy within the previous 3 weeks prior to
                  lymphodepletion.

        Eligibility criteria to be met prior to cell infusion after lymphodepletion:

          -  No evidence of uncontrolled infection or sepsis.

          -  Negative serum pregnancy within 7 days of cell infusion (does not need to be repeated
             if pre-lymphodepletion pregnancy test is within window).